TY - JOUR
T1 - Family History Associates With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases
AU - Samadder, N. Jewel
AU - Valentine, John F.
AU - Guthery, Stephen
AU - Singh, Harminder
AU - Bernstein, Charles N.
AU - Leighton, Jonathan A.
AU - Wan, Yuan
AU - Wong, Jathine
AU - Boucher, Kenneth
AU - Pappas, Lisa
AU - Rowe, K.
AU - Burt, Randall W.
AU - Curtin, K.
AU - Smith, K. R.
N1 - Funding Information:
Funding Support for this project was provided by the Crohn's and Colitis Foundation of America Senior Research Award (N.J.S.), National Cancer Institute grants P01-CA073992 and R01-CA040641 (R.W.B.), and a Junior Faculty Career Development Award from the American College of Gastroenterology (N.J.S.). Partial support for the Utah Population Database and this project was provided by the Huntsman Cancer Institute Cancer Center Support grant P30CA042014 from the National Cancer Institute and the Huntsman Cancer Foundation. Support for the Utah Cancer Registry is provided by contract HHSN 261201000026C from the National Cancer Institute with additional support from the Utah Department of Health and the University of Utah. The funding sources did not play a role in the design, conduct, or reporting of the study or in the decision to submit the manuscript for publication. Conflicts of interest These authors disclose the following: N. Jewel Samadder is a consultant for Cook Medical, Cancer Prevention Pharmaceuticals, Inc, and Janssen Research and Development; Charles N. Bernstein has consulted for AbbVie Canada, Ferring Canada, Janssen Canada, Pfizer Canada, Shire Canada, Takeda Canada, Mylan Pharmaceuticals, and 4D-Pharma; and Harminder Singh has consulted for Pendopharm and Merck Canada, and has received a research grant from Merck Canada. The remaining authors disclose no conflicts. Funding Support for this project was provided by the Crohn's and Colitis Foundation of America Senior Research Award (N.J.S.), National Cancer Institute grants P01-CA073992 and R01-CA040641 (R.W.B.), and a Junior Faculty Career Development Award from the American College of Gastroenterology (N.J.S.). Partial support for the Utah Population Database and this project was provided by the Huntsman Cancer Institute Cancer Center Support grant P30CA042014 from the National Cancer Institute and the Huntsman Cancer Foundation. Support for the Utah Cancer Registry is provided by contract HHSN 261201000026C from the National Cancer Institute with additional support from the Utah Department of Health and the University of Utah. The funding sources did not play a role in the design, conduct, or reporting of the study or in the decision to submit the manuscript for publication.
Funding Information:
Funding Support for this project was provided by the Crohn’s and Colitis Foundation of America Senior Research Award (N.J.S.), National Cancer Institute grants P01-CA073992 and R01-CA040641 (R.W.B.), and a Junior Faculty Career Development Award from the American College of Gastroenterology (N.J.S.). Partial support for the Utah Population Database and this project was provided by the Huntsman Cancer Institute Cancer Center Support grant P30CA042014 from the National Cancer Institute and the Huntsman Cancer Foundation . Support for the Utah Cancer Registry is provided by contract HHSN 261201000026C from the National Cancer Institute with additional support from the Utah Department of Health and the University of Utah. The funding sources did not play a role in the design, conduct, or reporting of the study or in the decision to submit the manuscript for publication.
Publisher Copyright:
© 2019 AGA Institute
PY - 2019/8
Y1 - 2019/8
N2 - Background & Aims: Individuals with inflammatory bowel diseases (IBDs) have an increased risk of developing colorectal cancer (CRC). Although family history of CRC is a well-established risk factor in healthy individuals, its role in patients with IBD is less clear. We aimed to estimate the risk of CRC in a cohort of patients with IBD from Utah and the significance of family history of CRC in a first-degree relative (FDR). Methods: We identified Utah residents with IBD, using the Intermountain Healthcare and University of Utah Health Sciences databases, from January 1, 1996, through December 31, 2011. CRCs were identified using the Utah Cancer Registry and linked to pedigrees from the Utah Population Database. CRC incidence was compared with that of the state population by standardized incidence ratios (SIRs). Results: A cohort of 9505 individuals with IBD was identified and 101 developed CRC during the study period. The SIR for CRC in patients with Crohn's disease was 3.4 (95% CI, 2.3–4.4), and in patients with ulcerative colitis was 5.2 (95% CI, 3.9–6.6). Patients with IBD and a concurrent diagnosis of primary sclerosing cholangitis had the greatest risk of CRC (SIR, 14.8; 95% CI, 8.3–21.2). A history of CRC in a FDR was associated with a nearly 8-fold increase in risk of CRC in patients with IBD (SIR, 7.9; 95% CI, 1.6–14.3), compared with the state population. Conclusions: Patients with IBD have a 3- to 5-fold increase in risk of CRC, and those with CRC in a FDR have an almost 8-fold increase in risk. Family history may act as a simple measure to identify individuals with IBD at highest risk for CRC and indicates the need for enhanced surveillance in this population.
AB - Background & Aims: Individuals with inflammatory bowel diseases (IBDs) have an increased risk of developing colorectal cancer (CRC). Although family history of CRC is a well-established risk factor in healthy individuals, its role in patients with IBD is less clear. We aimed to estimate the risk of CRC in a cohort of patients with IBD from Utah and the significance of family history of CRC in a first-degree relative (FDR). Methods: We identified Utah residents with IBD, using the Intermountain Healthcare and University of Utah Health Sciences databases, from January 1, 1996, through December 31, 2011. CRCs were identified using the Utah Cancer Registry and linked to pedigrees from the Utah Population Database. CRC incidence was compared with that of the state population by standardized incidence ratios (SIRs). Results: A cohort of 9505 individuals with IBD was identified and 101 developed CRC during the study period. The SIR for CRC in patients with Crohn's disease was 3.4 (95% CI, 2.3–4.4), and in patients with ulcerative colitis was 5.2 (95% CI, 3.9–6.6). Patients with IBD and a concurrent diagnosis of primary sclerosing cholangitis had the greatest risk of CRC (SIR, 14.8; 95% CI, 8.3–21.2). A history of CRC in a FDR was associated with a nearly 8-fold increase in risk of CRC in patients with IBD (SIR, 7.9; 95% CI, 1.6–14.3), compared with the state population. Conclusions: Patients with IBD have a 3- to 5-fold increase in risk of CRC, and those with CRC in a FDR have an almost 8-fold increase in risk. Family history may act as a simple measure to identify individuals with IBD at highest risk for CRC and indicates the need for enhanced surveillance in this population.
KW - Colitis-Associated Cancer
KW - Colon Cancer
KW - Genetics
KW - PSC
KW - SIRs
UR - http://www.scopus.com/inward/record.url?scp=85063859400&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063859400&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2018.09.038
DO - 10.1016/j.cgh.2018.09.038
M3 - Article
C2 - 30267862
AN - SCOPUS:85063859400
SN - 1542-3565
VL - 17
SP - 1807-1813.e1
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 9
ER -